Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | PHGDH | O43175 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1876940 | 0.86 | RECQL (0.72) | RECQLKCNJ1KCNH2KMT2APOLB | |
| SCHEMBL2384676 | 0.85 | RECQL (0.70) | RECQLKCNJ1KCNH2KMT2APOLB | |
| SCHEMBL6607225 | 0.84 | RECQL (0.68) | RECQLKCNJ1KCNH2KMT2APOLB | |
| SCHEMBL367862 | 0.83 | SIGMAR1 (0.63) | KMT2APOLBMEN1ALDH1A1KDM4E | |
| SCHEMBL4994038 | 0.83 | ALDH1A1 (0.67) | KCNJ1KCNH2KMT2AALDH1A1LMNA | |
| SCHEMBL6287119 | 0.82 | ALDH1A1 (0.62) | KCNJ1KCNH2KMT2AALDH1A1LMNA | |
| SCHEMBL2747017 | 0.82 | KCNJ1 (0.73) | RECQLKCNJ1KCNH2KMT2APOLB | |
| SCHEMBL5302733 | 0.82 | KMT2A (0.60) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL9557210 | 0.81 | ALDH1A1 (0.61) | KCNJ1KCNH2KMT2AALDH1A1LMNA | |
| SCHEMBL10666879 | 0.81 | NPC1 (0.65) | RECQLKMT2AALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414054-B2 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| WO-2007018941-A2 | PYRIMIDYL-THIOPHENE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20060194863-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-08-31 | — | — | US | disclosed |
| US-7098236-B2 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2006-08-29 | — | — | US | disclosed |
| US-20060063940-A1 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-03-23 | — | — | US | disclosed |
| US-7015220-B2 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20060025413-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-02-02 | — | — | US | disclosed |
| US-20050228036-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2005-10-13 | — | — | US | disclosed |
| WO-2005037257-A2 | NOVEL ALANYL-AMINO PEPTIDASE INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES | IMTM GMBH (DE) | 2005-04-28 | — | — | WO | disclosed |
| US-20040198720-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ANDREWS STEVEN W (US) | 2004-10-07 | — | — | US | disclosed |
| US-6765012-B2 | FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION | ALLERGAN, INC. | 2004-07-20 | — | — | US | disclosed |
| EP-1430048-A1 | 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | Allergan, Inc. (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20030225152-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030199478-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003027102-A1 | 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228036-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | RECQL 4408/4885KCNJ1 3684/4885KCNH2 2404/4885 |
| US-20030199478-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | RECQL 4408/4885KCNJ1 3684/4885KCNH2 2404/4885 |
| US-20060194863-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | RECQL 4408/4885KCNJ1 3684/4885KCNH2 2404/4885 |
| US-20060025413-A1 | 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | RECQL 4408/4885KCNJ1 3684/4885KCNH2 2404/4885 |
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | DNPEP, PREP, ANPEP | RECQL 4183/4885KCNJ1 3337/4885KCNH2 3519/4885 |
| US-20060063940-A1 | 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | RECQL 4408/4885KCNJ1 3684/4885KCNH2 2404/4885 |
| US-20030225152-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | RECQL 4408/4885KCNJ1 3684/4885KCNH2 2404/4885 |
| US-20040198720-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | RECQL 4408/4885KCNJ1 3684/4885KCNH2 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.